Dr. Klaus Dembowsky has more than 25 years experience in research and development for pharmaceutical and biotech companies. After earning his medical degree in Heidelberg he was working in neurophysiological research and habilitated in 1988. He continued his career in the pharmaceutical industry where numerous innovative drugs were brought into clinical development under his leadership, one drug being on the market. After more than 10 years in the cardiovascular research institute at Bayer he served in different management positions in the biotech industry (VP Drug Discovery at Ingenium Pharmaceuticals, Managing Director at Speedel Experimenta, Chief Medical Officer at Polyphor). In May 2015 he was appointed CEO of amcure and strengthens the management team with his broad experience.
Dr. Matthias Klaften was working since as business development manager and consultant for Spin-Off projects in the department of innovation management at the Karlsruhe Institute of Technology (KIT). Dr. Klaften studied Biology in Karlsruhe and Munich. He worked for a US biotech company before he passed his PhD at the Institute for Experimental Genetics at the Helmholtz Zentrum München. As a project leader he was in charge of several innovation projects for medical technology funded by the Helmholtz Society, by the Federal Ministry of Education and Research (BMBF) and the Federal Ministry of Economics and Technology (BMWi). He has expertise in the development of high-tech projects and provided advice for biotech start-up projects and companies. As Chief Operating Officer and Chief Financial Officer he takes over the operative management of amcure and is responsible for business development and fundraising.
Dr. Alexandra Matzke worked as postdoctoral fellow at the Institute of Toxikology (ITG) and Genetics at the KIT. During her PhD at the Research Center Karlsruhe (now KIT) she developed the CD44v6 blocking peptides and investigated their inhibitory effect in cancer. These peptides are the basis of the R&D activities of amcure. As project leader she was in charge of several innovation projects dealing with the development of CD44v6 blocking agents towards therapeutic use funded by the Helmholtz Society and the Federal Ministry of Economics and Technology (BMWi). As Chief Scientific Officer she is part of the management team of amcure and takes over responsibility for the R&D project pipeline.
Prof. Dr. Helmut Ponta was group leader at the ITG with focus on understanding mechanisms of tumour metastasis. He is an internationally recognised expert for CD44 with broad contacts in the research area of signal transduction and cancer.
Prof. Dr. Véronique Orian-Rousseau is group leader at the ITG. Her group consisting of two post-docs, seven PhD students and a technical assistant is a collaboration partner of amcure and focuses on the cooperativity between cell adhesion molecules and receptor tyrosine kinases in tumor progression and in development.